Monthly Versus Daily Buprenorphine Formulations for Treatment of Opiate Use Disorder
Status:
Not yet recruiting
Trial end date:
2024-12-01
Target enrollment:
Participant gender:
Summary
Opioid use disorder and opioid-related deaths are increasing across Canada. The mainstay of
medical treatment includes either full (methadone) or partial (buprenorphine) opioid agonist
therapy. In Canada, there are 2 buprenorphine formulations, an immediate-release (Suboxone)
and extended-release(Sublocade). These treatments have been shown to be equivalent for
medication adherence and treatment retention. However, Sublocade costs 8-times more, and 50%
of patients must pay out-of-pocket if they prefer this treatment option. This study is needed
to demonstrate the superior benefits of Sublocade on important clinical outcomes to
demonstrate its cost-effectiveness and justify expanded insured access across Canada.